-

Slingshot Biosciences, Inc. Partners With Palex Medical to Distribute Synthetic Cells Throughout Spain and Portugal

EMERYVILLE, Calif.--(BUSINESS WIRE)--SLINGSHOT BIOSCIENCES, INC. the developers of synthetic cells, today announced they have extended their distribution channel through a new agreement with Palex Medical, a company group dedicated to providing advanced solutions in the hospital and research sectors.

The agreement entitles Palex Medical the rights to distribute and resell Slingshot Bio’s complete product line-up in Spain and Portugal. Through Palex’s network of customers, Slingshot Bio will be able to establish its presence in the markets of Spain and Portugal, with the well-established presence and expertise of Palex who has been selling into flow cytometry for many years.

Palex’s network will provide us with the market penetration needed to reach our full sales potential. Slingshot Biosciences has considered many distribution partners and we are confident that Palex’s extensive knowledge in the field, prominent presence and large customer base will help us leverage our position in the flow cytometry market,” said Jeffrey Kim, CEO & Founder.

Slingshot Bio’s synthetic cellular controls provide consistent, precise, accurate control for research users in the flow cytometry space by mimicking blood properties as detected by flow cytometry. The ability to manufacture consistent controls for flow cytometry has been missing for decades and is now accurately reproducible with Slingshot Bio’s unique manufacturing platform. “Slingshot bio is a company that provides cutting edge solutions in the flow cytometry sector, which completes our portfolio and helps us to strengthen our position as leaders in this market in Spain and Portugal,” said Xavier Carbonell, CEO of Palex Medical.

About Slingshot Biosciences, Inc.

Founded in 2012, Slingshot Biosciences is a fast-growing life sciences company with a platform technology and paradigm-shifting mission to make synthetic cells the gold standard for all cell-based applications—including diagnostics, and adoptive cell therapy development and instrument calibration. Learn more at www.slingshotbio.com

About Palex Medical S.A:

Founded in 1955, Palex Medical is a group of companies with more than 600 people working together, whose main features are its support to health and research professionals, its dedication to the quest for innovation in products, equipment and systems, and its perseverance in maintaining a high level of quality in all areas of its business activity. Learn more at https://www.palexmedical.com/en/

Contacts

Caitlin Farquhar
pr@slingshotbio.com

Slingshot Biosciences, Inc.


Release Versions

Contacts

Caitlin Farquhar
pr@slingshotbio.com

More News From Slingshot Biosciences, Inc.

Slingshot Biosciences Appoints Glenn Bilawsky as CEO to Lead Strategic Expansion across Clinical Trial and Diagnostic Markets

EMERYVILLE, Calif.--(BUSINESS WIRE)--Slingshot Biosciences, a leader in precision-engineered cell mimics, has appointed Glenn Bilawsky as Chief Executive Officer. He succeeds Founder and former CEO Jeffrey Kim, PhD, who will remain actively involved as a Senior Advisor and Board Director. This transition is a strategic inflection point as Slingshot scales to meet rising global demand for cell mimics as standardized, reliable alternatives to biological controls. The widespread adoption of its Tr...

Slingshot Biosciences Debuts TruCytes™ Potency—Cell Mimics for Scalable, Reproducible CAR-T Potency Assays

EMERYVILLE, Calif.--(BUSINESS WIRE)--Slingshot Biosciences, the leader in precision-engineered cell mimic technologies, today announced the launch of TruCytes™ Potency, a new class of biomarker cell mimics specifically designed for functional CAR-T potency assays. TruCytes Potency cell mimics offer a customizable, scalable, and efficient alternative to cell line target cells. This helps CAR-T developers accelerate assay validation and lot release, while avoiding the operational burden, variabil...

Slingshot Biosciences Welcomes Visionary Leader and Industry Expert Dr. Nimisha Srivastava as New Chief Operations Officer

EMERYVILLE, Calif.--(BUSINESS WIRE)--Slingshot Biosciences today announced the addition of Nimisha Srivastava, Ph.D., as Chief Operations Officer. Dr. Srivastava brings more than 20 years of experience in nanofluidics, synthetic biology technology development, and operational scale-up, as well as a proven track record of building high-performing technical teams. Dr. Srivastava’s expertise in scaling disruptive technologies will be instrumental in establishing Slingshot Biosciences’ customizable...
Back to Newsroom